RxDoctor Payments Data

Charles Shiver, MD

Internal Medicine · Milledgeville, GANPI 1376574905

Payments from drug & device makers

$627in general payments, 2019–2025

Across 34 payments — averaging $18.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$187
  • Novo Nordisk$163
  • AbbVie$68
  • Amgen$40
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$25
  • Phadia US Inc.$24
  • plus $121 from 8 others

What the payments were for

  • Food & beverage$627100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$627 in reported general payments places this provider in the 60th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$78,995
Medicare patients
334
Services billed
919

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide168$176,131
EliquisApixaban175$170,348
RybelsusSemaglutide109$164,520
OzempicSemaglutide81$119,454
JanuviaSitagliptin Phosphate98$80,013
XareltoRivaroxaban58$65,952
FarxigaDapagliflozin Propanediol44$48,181
TrulicityDulaglutide26$39,350
JardianceEmpagliflozin35$35,396
Trelegy ElliptaFluticasone/Umeclidin/Vilanter43$34,887
Tresiba Flextouch U-200Insulin Degludec25$18,272
Soliqua 100-33Insulin Glargine/Lixisenatide14$15,733
MyrbetriqMirabegron21$15,457
Repatha SureclickEvolocumab14$13,719
Candesartan Cilexetil122$11,722

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus, Ozempic$163$283,974190 claims
Lilly USA, LLCMounjaro, Trulicity$16$215,480194 claims
PfizerEliquis$15$170,348175 claims
MerckJanuvia, Belsomra$12$87,695112 claims
AstraZenecaFarxiga, Symbicort$187$53,11065 claims
Boehringer IngelheimJardiance, Tradjenta$13$39,10150 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$20$15,73314 claims
AbbVieSynthroid$68$4,33852 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Milledgeville

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →